Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: A randomized controlled trial

Wonyoung Choi, Jong Gwang Kim, Seung Hoon Beom, Jun Eul Hwang, Hyun Jung Shim, Sang Hee Cho, Min Ho Shin, Sin Ho Jung, Ik Joo Chung, Joon Young Song, Woo Kyun Bae

Research output: Contribution to journalArticle

Abstract

Purpose Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies. Materials and Methods We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay. Results Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments. Conclusion The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalCancer Research and Treatment
Volume52
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Keywords

  • Chemotherapy
  • Colorectal neoplasms
  • Stomach neoplasms
  • Vaccination

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: A randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Choi, W., Kim, J. G., Beom, S. H., Hwang, J. E., Shim, H. J., Cho, S. H., Shin, M. H., Jung, S. H., Chung, I. J., Song, J. Y., & Bae, W. K. (2020). Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: A randomized controlled trial. Cancer Research and Treatment, 52(1), 246-253. https://doi.org/10.4143/crt.2019.189